



(WASHINGTON, June 18, 2024) — The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition in San Diego on December 7-10. This year's recipients are a group of pioneering scientists, innovative clinicians, and selfless mentors who have advanced hematology through vital contributions – from revolutionary achievements in cord blood transplants, hematopoietic stem cell research, and microbiome research to supporting medical students underrepresented in medicine.

“ASH is honored to recognize these outstanding hematologists, whose groundbreaking research, mentorship, and dedication have profoundly advanced the field,” said 2024 ASH President Mohandas Narla, DSc, distinguished scientist at New York Blood Center Enterprises. “These visionary leaders have left an indelible mark on hematology and made a lasting impact on the lives of those living with blood disorders.” The 2024 Honorific Award recipients are:

**Éliane Gluckman, MD, PhD**, University of Paris  
[Wallace H. Coulter Award for Lifetime Achievement in Hematology](#)

Dr. Gluckman, a renowned physician-scientist and thought leader, is being recognized for a lifetime of achievement in cord blood transplantation. She performed the world's first human cord blood transplant, which established cord blood as an alternative stem cell source for patients in need of hematopoietic cell transplantation and shortened the delay between donor identification and actual transplant. Since that revolutionary procedure in 1988, there have been more than 40,000 transplants, with cord blood registries established worldwide.

As a young medical student, Dr. Gluckman was drawn to hematology, a relatively new discipline at the time, because of its potential for growth and innovation. Her first residency position was in the hematology ward at the Hôtel-Dieu Hospital in Paris, where she affirmed her passion and interest in Fanconi anemia and sickle cell disease (SCD). From 1988, she led cord blood research as medical director of the bone marrow transplant service and head of the department of hematology at the Saint-Louis Hospital in Paris. Currently, she is head of the EuroCord research group on cell therapy for malignant and non-malignant diseases in children.

Dr. Gluckman has continued to shape hematology. Her impact includes significant contributions to the understanding of hematologic disorders such as aplastic anemia, Fanconi anemia, and sickle cell disease through the design of new conditioning protocols that are used to prepare patients for stem cell transplantation.

Dr. Gluckman is currently leading a project that examines immunogenetic factors that could predict the outcomes and probability of finding a donor for stem cell transplants in people living with sickle cell disease and other hereditary disorders. She has trained many investigators in the field and helped establish bone marrow transplant units in their respective countries.

X: [https://twitter.com/ASH\\_hematology/status/1803077283172733370](https://twitter.com/ASH_hematology/status/1803077283172733370)

Facebook: <https://fb.watch/sNrTYqAX8a/>

Instagram: [https://www.instagram.com/reel/C8XH46jio\\_w/?utm\\_source=ig\\_web\\_copy\\_link&igsh=MzRIODBiNWFIZA==](https://www.instagram.com/reel/C8XH46jio_w/?utm_source=ig_web_copy_link&igsh=MzRIODBiNWFIZA==)

LinkedIn: [https://www.linkedin.com/posts/american-society-of-hematology\\_ashkudos-ashawards-ash24-activity-7208847238746255361-vysN?utm\\_source=share&utm\\_medium=member\\_desktop](https://www.linkedin.com/posts/american-society-of-hematology_ashkudos-ashawards-ash24-activity-7208847238746255361-vysN?utm_source=share&utm_medium=member_desktop)

